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In the past decade, mechanisms underlying allergic contact dermatitis have been intensively investigated by using
contact hypersensitivity (CHS) models in mice. However, the regulatory mechanisms, which could be applicable
for the treatment of allergic contact dermatitis, are still largely unknown. To determine the roles of B and T
lymphocyte attenuator (BTLA), a CD28 family coinhibitory receptor, in hapten-induced CHS, BTLA-deficient
(BTLA / ) mice and littermate wild-type (WT) mice were subjected to DNFB-induced CHS, severe combined
immunodeficient (SCID) mice were injected with CD4þ Tcells, and CD8þ T cells from either WTmice or BTLA /
mice were subjected to CHS. BTLA / mice showed enhanced DNFB-induced CHS and proliferation and IFN-g
production of CD8þ T cells as compared with WTmice. SCID mice injected with WT CD4þ T cells and BTLA /
CD8þ T cells exhibited more severe CHS as compared with those injected with WT CD4þ T cells and WT CD8þ T
cells. On the other hand, SCID mice injected with BTLA / CD4þ T cells and WT CD8þ T cells exhibited similar
CHS to those injected with WT CD4þ T cells and WT CD8þ T cells. Finally, to evaluate the therapeutic potential of
an agonistic agent for BTLA on CHS, the effects of an agonistic anti-BTLA antibody (6A6) on CHS were examined.
In vivo injection of 6A6 suppressed DNFB-induced CHS and IFN-g production of CD8þ T cells. Taken together,
these results suggest that stimulation of BTLA with agonistic agents has therapeutic potential in CHS.
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INTRODUCTION
Allergic contact dermatitis is a delayed type hypersensitivity
reaction to foreign substances and hapten-modified proteins
(Usatine and Riojas, 2010). Numerous studies using murine
models of contact hypersensitivity (CHS), which is induced by
epicutaneous exposure of haptens in sensitized mice, revealed
detailed immunological mechanisms (Martin et al., 2011;
Kaplan et al., 2012). During the sensitization phase of CHS,
hapten-modified proteins are loaded onto epidermal
Langerhans cells, which migrate from the epidermis to the
regional draining lymph nodes, where priming of hapten-
specific CD4þ T cells and CD8þ T cells occurs (Kaplan,
2010; Kaplan et al., 2012). During the elicitation phase of
CHS, hapten skin painting induces the recruitment of hapten-
specific T cells into the skin, leading to the development of
skin inflammation (Martin, 2004). Several studies have
demonstrated that CHS to DNFB is regulated by the balance
between IFN-g-producing CD8þ T cells as effector cells and
IL-4-producing CD4þ T cells as inhibitory cells (Vocanson
et al., 2009). However, regulatory mechanisms, which could
be applicable for the treatment of allergic contact dermatitis,
remain poorly understood.
The quality and quantity of T-cell responses are controlled
not only by signals through T-cell receptors (TCRs) but also by
the balance of secondary signals through costimulatory and
coinhibitory receptors (Greenwald et al., 2005). B and T
lymphocyte attenuator (BTLA), a coinhibitory receptor with
cytoplasmic immunoreceptor tyrosine-based inhibitory motifs
(Murphy et al., 2006; Cai and Freeman, 2009; Murphy and
Murphy, 2010), has been reported to attenuate TCR-mediated
signaling and proliferation of CD4þ T cells and CD8þ T cells
(Murphy et al., 2006; Cai and Freeman, 2009; Murphy and
Murphy, 2010). In vivo, it has been shown that BTLA has
inhibitory roles in a number of CD4þ T-cell-mediated disease
models (Watanabe et al., 2003; Deppong et al., 2006;
Tamachi et al., 2007). In addition, recent reports have
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revealed that BTLA also has a role in the regulation of CD8þ
T-cell function (Tao et al., 2005; Krieg et al., 2007; Liu et al.,
2009; Derre´ et al., 2010). However, roles of BTLA in the
regulation of hapten-induced CHS remain unknown.
In this study, we found that DNFB-induced CHS was
significantly enhanced in BTLA / mice. Cell transfer experi-
ments revealed that BTLA expressed on CD8þ T cells had an
inhibitory role in CHS. DNFB sulfonic acid (DNBS)–induced
proliferation was enhanced in BTLA / CD8þ T cells but not
in BTLA / CD4þ T cells. In vivo injection of an agonistic
anti-BTLA antibody inhibited IFN-g production of CD8þ T
cells and CHS. These results indicate that BTLA functions as a
negative regulator of hapten-induced CHS by attenuating
CD8þ T-cell activation, and that BTLA could be a therapeutic
target in allergic contact dermatitis.
RESULTS
DNFB-induced CHS is enhanced in BTLA / mice
To determine whether BTLA is involved in CHS, we first
compared DNFB-induced CHS in BTLA / mice and litter-
mate wild-type (WT) mice. BTLA / mice and WT mice in
BALB/c background were sensitized on the shaved abdomen
with DNFB and 5 days later, the ear was painted with DNFB.
As shown in Figure 1, BTLA / mice exhibited enhanced ear
thickness (Figure 1a) and severe inflammation (Figure 1b,
n¼8, Po0.01) as compared with WT mice. We next
analyzed leukocytes recovered from the ear in mice chal-
lenged with DNFB by flow cytometry and found that the
numbers of CD4þ T cells, CD8þ T cells, Gr-1þ cells, and
F4/80þ cells were increased in BTLA / mice as compared
with those in WT mice (Figure 1c, n¼ 6, Po0.01). These
results indicate that BTLA functions as an attenuator in the
development of hapten-induced CHS.
Importantly, CD8þ T cells expressed lower levels of BTLA
than CD4þ T cells at the inflammatory sites (Figure 1d; CD4þ
76.8±5.8 vs. CD8þ 18.3±3.5; mean fluorescence intensity,
n¼5, Po0.01), whereas the expression levels of BTLA on
naive CD8þ T cells in lymph nodes were similar to those on
naive CD4þ T cells (Supplementary Figure S1 online). On the
other hand, DNFB challenge did not change the expression of
herpesvirus entry mediator, a ligand of BTLA, on dermal
dendritic cells and Langerhans cells (Supplementary Figure
S2 online). Moreover, CD8þ T cells recovered from the ear in
DNFB-challenged BTLA / mice produced higher levels of
IFN-g than those in DNFB-challenged WT mice (WT
218.4±8.8 vs. BTLA / 332.5±10.5; mean fluorescence
intensity, n¼5, Po0.01) (Figure 1e), suggesting that BTLA
limits CD8þ T-cell-mediated functions on a per cell basis.
Taken together with previous studies showing that the
expression of BTLA on CD8þ T cells is downregulated in
effector CD8þ T cells (Derre´ et al., 2010; Serriari et al., 2010),
these results suggest that CD8þ T cells at the site of CHS in
BTLA / mice are in an effector state.
Effector CD8þ T cells are increased in the draining lymph nodes
in DNFB-sensitized BTLA / mice
To address the mechanisms underlying the enhanced DNFB-
induced CHS in BTLA / mice, we next examined the
activation status of T cells in the draining lymph nodes in
DNFB-sensitized BTLA / mice and WT mice. Although no
significant difference was found in the frequency of effector
CD4þ T cells (CD44high LY6Clow CD4þ cells) in BTLA /
mice and WT mice (Figure 2a, n¼ 5), the frequency of effector
CD8þ T cells (CD44high LY6Clow CD8þ cells) was significantly
increased in the draining lymph nodes of DNFB-sensitized
BTLA / mice as compared with those of DNFB-sensitized
WT mice (Figure 2b, n¼5, Po0.01). On the other hand, the
expression levels of CXCR3, a chemokine receptor allowing
effector T cells to enter peripheral tissues (Zhang and Bevan,
2011), on CD44high LY6Clow CD8þ cells were similar in
DNFB-sensitized BTLA / mice and WT mice (Figure 2c,
n¼5). These data suggest that in addition to the inhibitory
effect of BTLA on CD8þ T-cell-mediated functions on a per
cell basis (Figure 1e), the enhanced expansion of effector
CD8þ T cells could be involved in the enhanced DNFB-
induced CHS in BTLA / mice.
It has been shown that regulatory T cells inhibit CHS by
attenuating the expansion of hapten-stimulated CD8þ T cells
(Dubois et al., 2003; Ring et al., 2006; Cavani. 2008;
Vocanson et al., 2009). Therefore, we next examined
FOXP3þ CD4þ T cells in the draining lymph nodes of
DNFB-sensitized BTLA / mice and WT mice. As shown in
Supplementary Figure S3a online, the frequency of FOXP3þ
CD4þ T cells in the draining lymph nodes of DNFB-sensitized
BTLA / mice was similar to those in DNFB-sensitized WT
mice (n¼ 5). The expression levels of GITR, CTLA4, and
CD25 on FOXP3þ CD4þ T cells were also similar in DNFB-
sensitized BTLA / mice and WT mice (Supplementary
Figure S3b online), indicating that regulatory T cells are
similarly developed during CHS in BTLA / mice and WT
mice. Recent studies have shown that among regulatory T
cells, an ICOSþ subpopulation strongly inhibits hapten-
specific CD8þ T cells as compared with an ICOS subpopu-
lation (Vocanson et al., 2010; Gomez de Agu¨ero et al., 2012).
However, as shown in Supplementary Figure S4 online, the
frequency of ICOSþ CD25þ T cells in the draining lymph
nodes of DNFB-sensitized BTLA / mice was similar to that
of DNFB-sensitized WT mice (n¼5). We also found that the
number of FOXP3þ CD4þ T cells recovered from the ear and
IL-10 production in FOXP3þ CD4þ T cells in DNFB-
challenged BTLA / mice were similar to those in DNFB-
challenged WT mice (Supplementary Figure S5 online). These
results suggest that BTLA expressed on FOXP3þ CD4þ T cells
may not be involved in the regulation of hapten-induced CHS.
BTLA expressed on CD8þ T cells is involved in the attenuation
of DNFB-induced CHS
To address the cellular mechanisms underlying the enhanced
DNFB-induced CHS in BTLA / mice, SCID mice that were
injected with a mixture of CD4þ T cells and CD8þ T cells
from either BTLA / mice or WT mice were subjected to
DNFB-induced CHS. Importantly, SCID mice injected with
WT CD4þ T cells and BTLA / CD8þ T cells exhibited
enhanced ear thickness (n¼ 8, Po0.01) (Figure 3a), severe
inflammation in the ear (n¼ 8) (Figure 3b), and increased
numbers of IFN-g-producing CD8þ T cells in the ear (n¼6,
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Figure 1. Contact hypersensitivity is enhanced in B and T lymphocyte attenuator–deficient (BTLA / ) mice. BTLA / mice and littermate wild-type (WT) mice
on the BALB/c background were sensitized with DNFB, and 5 days after DNFB sensitization, mice were challenged with DNFB on the ear. (a) Ear swelling was
quantified by the measurements of ear thickness before (baseline) and 1, 2, 3, 4, and 5 days after the challenge. Shown are means±SD (n¼ 8 mice in each group)
of the increase in the ear thickness from the baseline. *Significantly different from the mean value of WT mice, *Po0.01. (b) Five days after the challenge with
DNFB, specimens of the ear from BTLA / mice (n¼ 6) and littermate WT mice (n¼ 6) were stained with hematoxylin and eosin. Representative
photomicrographs are shown. (c) Five days after the challenge with DNFB, leukocytes were isolated from the ear and analyzed as described in the Materials and
Methods. Shown are means±SD (n¼6 mice in each group) of the numbers of CD4þ cells, CD8þ cells, Gr-1þ cells, and F4/80þ cells. *Significantly different
from the mean value of WT mice, *Po0.01. (d) Five days after the challenge with DNFB, the expression of BTLA on CD4þ cells and CD8þ cells isolated from the
ear was examined by flow cytometry. Shown are representative histograms with mean fluorescence intensity (MFI) and means±SD (n¼ 5, each) of the MFI of anti-
BTLA staining. *Po0.01. (e) Two days after the challenge with DNFB, the expression of IFN-g in CD8þ cells isolated from the ear was examined by flow
cytometry. Shown are representative histograms with MFI and means±SD (n¼ 5, each) of the MFI of anti-IFN-g staining. *Po0.01. Data are representative of three
independent experiments. nd, not detectable. Bar¼ 200mm.
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Po0.01) (Figure 3c) as compared with those injected with WT
CD4þ T cells and WT CD8þ T cells. Similarly, SCID mice
injected with BTLA / CD4þ T cells and BTLA / CD8þ T
cells exhibited enhanced ear thickness, severe inflammation in
the ear, and increased numbers of IFN-g-producing CD8þ T
cells in the ear as compared with those injected with
BTLA / CD4þ T cells and WT CD8þ T cells (Figure 3,
Po0.01). These results suggest that BTLA expressed on CD8þ
T cells is involved in the attenuation of DNFB-induced CHS.
On the other hand, SCID mice injected with BTLA /
CD4þ T cells and WT CD8þ T cells exhibited similar DNFB-
induced CHS to those injected with WT CD4þ T cells and
WT CD8þ T cells, suggesting that BTLA expressed on CD4þ
T cells is not significantly involved in the regulation of DNFB-
induced CHS.
DNBS-induced cell proliferation, cytokine production, and
exocytosis are enhanced in BTLA / CD8þ T cells
To clarify the basis for the enhanced CHS in BTLA / mice in
detail, hapten-induced proliferation and cytokine production
of CD4þ T cells and CD8þ T cells in BTLA / mice were
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Figure 2. Effector CD8þ T cells but not CD4þ T cells are increased in the draining lymph nodes of DNFB-sensitized B and T lymphocyte attenuator–deficient
(BTLA / ) mice. BTLA / mice and littermate wild-type (WT) mice were sensitized with DNFB on the arms and legs. Five days after the sensitization, cells
from inguinal and axillary lymph nodes were analyzed by flow cytometry. (a, b) Shown are representative dot plots of CD44 vs. LY6C staining and means±SD (n¼5,
each) of the frequency of effector population (CD44high LY6Clow cells) of (a) CD4þ T cells and (b) CD8þ T cells. *Po0.01. (c) Shown are representative histograms for
the CXCR3 expression on CD44high LY6Clow CD4þ cells or CD44high LY6Clow CD8þ cells. n¼ 5. Data are representative of three independent experiments.
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compared with those in WT mice. Five days after the
sensitization with DNFB, CD62Llow CD4þ T cells and
CD62Llow CD8þ T cells were isolated from the draining
lymph nodes in WT mice and BTLA / mice, and stimulated
with DNBS in the presence of irradiated splenic antigen-
presenting cells. Importantly, BTLA / CD8þ T cells showed
enhanced DNBS-induced proliferation (Figure 4a, n¼6,
Po0.01) and IFN-g production (Figure 4b, n¼6, Po0.01)
as compared with WT CD8þ T cells, whereas BTLA /
CD4þ T cells showed similar levels of DNBS-induced pro-
liferation (Figure 4a) and IL-4 production (Figure 4b) to WT
CD4þ T cells. As the release of perforin from CD8þ T cells by
exocytosis has been shown to be involved in CHS (Kehren
et al., 1999), we investigated DNBS-induced exocytosis of
CD8þ T cells by evaluating the surface expression of
CD107a, a marker of exocytosis of lymphocytes (Betts et al.,
2003). The expression of CD107a was significantly increased
in BTLA / CD8þ T cells on DNBS stimulation as compared
with WT CD8þ T cells (WT 60.2±5.7 vs. BTLA /
101.4±5.5; mean fluorescence intensity, n¼ 5, Po0.01)
(Figure 4c). These results indicate that BTLA attenuates not
only hapten-induced proliferation of CD8þ T cells but also
their functions on a per cell basis, suggesting that this
attenuation could be involved in the downregulation of
hapten-induced CHS.
An agonistic anti-BTLA mAb prevents CHS
Finally, to evaluate the therapeutic potential of BTLA stimula-
tion for allergic contact dermatitis, we examined the effect of
an agonistic anti-BTLA mAb (6A6) on DNFB-induced CHS in
WT mice (C57BL/6 background). As shown in Figure 5a, 6A6
significantly suppressed ear thickness (n¼6, Po0.001).
Importantly, even if 6A6 was injected to mice at 24 hours
after DNFB challenge, when CHS was being established, 6A6
suppressed ear thickness (Figure 5a). The injection of 6A6 at
24 hours after DNFB challenge also decreased the numbers of
CD4þ T cells, CD8þ T cells, Gr-1þ cells, and F4/80þ cells
recovered from the ear (Figure 5b, n¼ 6, Po0.01). As
expected, the injection of 6A6 did not attenuate DNFB-
induced CHS in BTLA / mice (Supplementary Figure S6
online), confirming that the inhibitory effect of 6A6 on CHS is
mediated by BTLA. The injection of 6A6 at 24 hours after
DNFB challenge also significantly decreased the number of
IFN-g-producing CD8þ T cells in the ear (Figure 5c, n¼6,
Po0.01). On the other hand, the injection of 6A6 did not
reduce the numbers of CD4þ T cells, CD8þ T cells, and
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FOXP3þCD4þ T cells in the spleen of WT mice
(Supplementary Figure S7 online). We also confirmed the
binding of 6A6 on CD8þ T cells in the ear of DNFB-
challenged WT mice (Figure 5d). Taken together, these results
suggest that 6A6 suppresses CHS by transducing inhibitory
signal through BTLA in CD8þ T cells rather than by depleting
cells expressing BTLA.
DISCUSSION
In this study, we show that BTLA expressed on CD8þ T cells
attenuates hapten-induced CHS presumably through the
suppression of proliferation and IFN-g production of effector
CD8þ T cells, and that agonistic agents for BTLA could be a
new therapeutic approach for CHS. We found that DNFB-
induced CHS was significantly enhanced in BTLA / mice
(Figure 1). We also found that effector CD8þ T cells were
increased in the draining lymph nodes in DNFB-sensitized
BTLA / mice (Figure 2), and that SCID mice injected with
BTLA / CD8þ T cells exhibited enhanced CHS as com-
pared with those injected with WT CD8þ T cells (Figure 3).
Furthermore, DNBS-induced proliferation, IFN-g production,
and exocytosis were enhanced in BTLA / CD8þ T cells
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(Figure 4). Finally, we showed that in vivo administration
of an agonistic anti-BTLA mAb suppressed CHS (Figure 5).
Taken together, these results suggest that BTLA expressed on
CD8þ T cells could be a therapeutic target for allergic contact
dermatitis.
We show that BTLA is involved in the attenuation of hapten-
induced CHS. Coinhibitory molecules of CD28 family, includ-
ing CTLA4, programmed cell death 1 (PD-1), and BTLA, have
been shown to attenuate T-cell-mediated immune responses
to varying degrees in various experimental settings (Chen,
2004). Previous studies have demonstrated that CTLA4
(Nuriya et al., 2001) and PD-1 (Tsushima et al., 2003) are
involved in the attenuation of hapten-induced CHS by
inhibiting the expansion of hapten-specific T cells. In this
study, we found that BTLA / mice exhibited enhanced
hapten-induced CHS (Figure 1) and the expansion of effector
CD8þ T cells (Figure 2). Taken together, it is indicated that all
of the coinhibitory molecules of the CD28 family participate
in the attenuation of hapten-induced CHS.
We also show that BTLA expressed on CD8þ T cells is
responsible for the attenuation of hapten-induced CHS. Pre-
vious studies investigating the roles of CTLA4 (Nuriya et al.,
2001) and PD-1 (Tsushima et al., 2003) in hapten-induced
CHS have not identified cell types whose expression of these
coinhibitory molecules are responsible for the attenuation of
CHS. On the other hand, we showed that SCID mice injected
with WT CD4þ T cells and BTLA / CD8þ T cells exhibited
enhanced CHS as compared with those injected with WT
CD4þ T cells and WT CD8þ T cells (Figure 3), whereas
hapten-induced CHS was similarly induced in SCID mice
injected with BTLA / CD4þ T cells and WT CD8þ T cells
and those injected with WT CD4þ T cells and WT CD8þ T
cells (Figure 3). We also found that hapten-induced prolifera-
tion, IFN-g production, and exocytosis were enhanced in
BTLA / CD8þ T cells (Figure 4), whereas hapten-induced
proliferation and IL-4 production were indistinguishable
between WT CD4þ T cells and BTLA / CD4þ T cells
(Figure 4). Given that IFN-g production (Vocanson et al.,
2009) and perforin release by exocytosis (Kehren et al., 1999)
are key events in CD8þ T-cell-mediated induction of CHS,
our results suggest that BTLA expressed on CD8þ T cells
attenuates hapten-induced CHS through the inhibition of
hapten-induced IFN-g production and perforin release of
CD8þ T cells.
Our results indicate that BTLA has inhibitory roles in CHS in
both the sensitization and the elicitation phase. We found that
effector CD8þ T cells were increased in the draining lymph
nodes in DNFB-sensitized BTLA / mice (Figure 2). We also
found that DNBS-induced proliferation, IFN-g production, and
exocytosis were enhanced in BTLA / CD8þ T cells recov-
ered from draining lymph nodes (Figure 4), indicating that
BTLA is involved in the sensitization phase of CHS. In
addition, we showed that in vivo injection of an agonistic
anti-BTLA mAb at 24 hours after DNFB challenge inhibited
CHS (Figure 5a), indicating that BTLA is involved in the
attenuation of CHS in the elicitation phase.
We found that not only the number of CD8þ T cells but
also the numbers of CD4þ T cells, Gr-1þ cells, and F4/80þ
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Figure 5. In vivo injection of an agonistic anti-B and T lymphocyte attenuator
(anti-BTLA) mAb inhibits contact hypersensitivity. C57BL/6 mice were
sensitized with DNFB and 5 days later mice were challenged with DNFB on
the ear. Either just before or 24 hours after DNFB challenge, an agonistic anti-
BTLA mAb (6A6) or control IgG was injected intraperitoneally to the mice.
(a) Ear swelling was quantified at 2 days after the challenge. Shown are
means±SD (n¼ 6 mice in each group) of the increase in the ear thickness from
the baseline. *Significantly different from the mean value of mice injected with
control IgG, **Po0.001, *Po0.01. (b) Two days after the challenge,
leukocytes were isolated from the ear and analyzed by flow cytometry. Shown
are means±SD (n¼6 mice in each group) of the numbers of CD4þ cells,
CD8þ cells, Gr-1þ cells, and F4/80þ cells. *Po0.01. Two days after the
challenge, leukocytes were isolated from the ear and (c) the number of IFN-g-
producing CD8þ T cells and (d) the binding of hamster IgG (6A6 or control
IgG) on CD8þ cells were analyzed by flow cytometry. Shown are means±SD
of (c) the numbers of IFN-gþ CD8þ cells recovered from the ear (n¼ 6 mice in
each group, *Po0.01) and (d) representative histograms for hamster IgG
binding on CD8þ cells (n¼5 mice in each group). Data are representative of
three independent experiments. nd, not detectable.
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cells were increased at the site of CHS in BTLA / mice as
compared with those of WT mice (Figure 1c). We also found
that the injection of the agonistic anti-BTLA antibody 6A6 at
24 hours after DNFB challenge suppressed the recruitment of
various cell populations into ear skin (Figure 5b). In this
regard, a recent study has shown that CD8þ T-cell-derived
IFN-g promotes the expression of proinflammatory cytokines
and chemokines, such as TNF-a, IL-17, CXCL1, and CXCL2, in
the hapten-challenged skin, resulting in the elicitation of CHS
(Kish et al., 2009). Therefore, it is possible that the increase in
various cell populations in the ear skin of BTLA / mice
(Figure 1c) as well as the reduction of various cell populations
by 6A6 may be because of the alteration of the levels of CD8þ
T-cell-derived IFN-g.
We also found that although the number of CD4þ T cells in
the draining lymph nodes of DNFB-sensitized BTLA / mice
was similar to that of DNFB-sensitized WT mice (Figure 2a),
the number of CD4þ T cells at the site of CHS was increased
in BTLA / mice compared with WT mice (Figure 1c). In
addition, we found that the expression of CXCR3, a chemo-
kine receptor that is mainly expressed in Th1-type CD4þ T
cells and effector CD8þ T cells and regulates their migration
(Groom and Luster, 2011), on CD44high LY6Clow CD4þ T
cells was indistinguishable between BTLA / mice and WT
mice (Figure 2c). These findings suggest that CXCR3 ligands
may not be the major chemokines for the recruitment of
CD4þ T cells at the site of CHS. Further studies are required to
address the mechanism underlying the enhanced CD4þ T-cell
infiltration at the site of CHS in BTLA / mice.
A previous study has shown that although BTLA is
expressed at low levels in FOXP3þ regulatory T cells,
FOXP3þ regulatory T cells in BTLA / mice exhibited
normal suppressive activity (Tao et al., 2008). In this study,
we found that the frequency of FOXP3þ CD4þ T cells in the
draining lymph nodes of DNFB-sensitized BTLA / mice
was similar to that of DNFB-sensitized WT mice
(Supplementary Figure S3a online). We also found that the
frequency of ICOSþ CD25þ T cells, a subpopulation of
regulatory T cells with strong suppressive activity on CHS
(Vocanson et al., 2010; Gomez de Agu¨ero et al., 2012), in the
draining lymph nodes of DNFB-sensitized BTLA / mice
was similar to that in DNFB-sensitized WT mice
(Supplementary Figure S4 online). Furthermore, we found
that the number and IL-10 production of FOXP3þ CD4þ T
cells recovered from the ear skin in CHS were similar
between WT mice and BTLA / mice (Supplementary
Figure S5 online). Taken together, these results suggest that
BTLA is not significantly involved in the regulation of
FOXP3þ regulatory T cells in hapten-induced CHS.
Our experiments using an agonistic anti-BTLA mAb (6A6)
have revealed that the agonistic agent for BTLA signaling has a
therapeutic potential for CHS, even though the agent is
administered to the sensitized mice at 24 hours after the
challenge. As it has been shown that 6A6 does not perturb
protective immunity against viral and bacterial infection
(Albring et al., 2010), it is suggested that agonistic agents for
BTLA could suppress CHS without the risk of infection.
Although agonistic anti-human BTLA antibody has not been
developed yet, our data provide a rationale for the
development of agonistic agents for the BTLA pathway for a
number of CD8þ T-cell-mediated immune diseases, including
allergic contact dermatitis.
The mode of action of 6A6 has been intensively examined
by recent studies (Lepenies et al., 2007; Albring et al., 2010). It
has been reported that 6A6 is indeed an agonistic antibody
rather than depleting antibody for cells expressing BTLA
(Lepenies et al., 2007; Albring et al., 2010). Consistent with
these studies, we found that in vivo injection of 6A6 at
24 hours after DNFB challenge decreased the number of
CD8þ T cells at the site of CHS (Figure 5) but not in the
spleen (Supplementary Figure S7 online). We also found that
6A6 more strongly decreased the number of IFN-g-producing
CD8þ T cells at the site of CHS (Figure 5), further supporting
the agonistic activity of 6A6 for BTLA. It has also been
reported that 6A6 suppresses the function of BTLA-expressing
cells even in herpesvirus entry mediator–deficient mice
(Lepenies et al., 2007; Albring et al., 2010), suggesting that
6A6 activates BTLA signaling independent of herpesvirus entry
mediator.
In conclusion, we show here that BTLA attenuates CHS
presumably by suppressing hapten-induced activation of
CD8þ T cells. Although further studies are required for
understanding the basis of the findings, our results should
highlight the therapeutic potential of agonistic agents for the
BTLA pathway for CD8þ T-cell-mediated immune diseases,
including allergic contact dermatitis.
MATERIALS AND METHODS
Mice
BTLA-deficient (BTLA / ) mice on BALB/c background and C57BL/6
background (Watanabe et al., 2003) were bred and housed in the
animal facility at Chiba University. SCID mice and C57BL/6 mice
were purchased from Japan SLC (Shizuoka, Japan). All mice were
housed in microisolator cages under specific pathogen-free
conditions and all experiments were conducted according to the
guidelines of Chiba University (approved ID; 21–11).
DNFB-induced CHS
Mice were sensitized on the shaved abdomen with 30ml of 0.5%
DNFB (Sigma-Aldrich, St Louis, MO) in acetone. Five days later, mice
were painted with 0.2% DNFB in acetone to the right ear (10ml to
each side) and acetone alone (as a negative control) to the left ear. Ear
swelling was quantified by three consecutive measurements of ear
thickness using a caliper.
Histological analysis
Samples of the ear pinna were fixed in 10% buffered formalin and
embedded in paraffin. Sections (4mm in thickness) were stained with
hematoxylin and eosin (HE).
Isolation of leukocytes from ear skin
The ear skin was cut into small pieces and incubated in RPMI
1640 medium containing Liberase TL (0.5 mg ml 1, Roche, Basel,
Switzerland) for 1 hour at 371C. A suspension of single cells was
separated from undigested tissue by passing through a 40-mm nylon
cell strainer.
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Flow cytometric analysis
Cells were stained and analyzed on a FACSCalibur (Becton Dick-
inson, San Jose, CA) using CELLQuest software. The following
antibodies were purchased: anti-CD4 (RM4-5, BioLegend, San Diego,
CA), anti-CD8a (53-6-7, BD Biosciences, San Jose, CA), anti-Gr-1
(RB6-8C5, BD Biosciences), anti-F4/80 (BM8, BioLegend), anti-BTLA
(6F7, eBioscience, San Diego, CA), anti-CD107a (1D4B,
BioLegend), anti-CD44 (IM7, BD Bioscience), anti-LY6C (AL-21, BD
Bioscience), anti-FOXP3 (FJK-16s, eBioscience), anti-GITR (DTA-1,
eBioscience), anti-CTLA4 (UC10-4B9, eBioscience), anti-CD25
(7D4, BD Bioscience), anti-CD207 (RMUL.2, eBioscience),
anti-ICOS (C398.4A, eBioscience), and anti-hamster IgG cocktail
(BD Bioscience). Before staining, Fc receptors were blocked with
anti-CD16/32 antibody (2.4G2; BioLegend). Negative controls con-
sisted of isotype-matched directly conjugated, nonspecific antibodies
(BD Biosciences).
Intracellular staining for IFN-c and IL-10
Cells recovered from the ear were incubated with monensin (2mM)
(Sigma-Aldrich) in RPMI1640 medium for 5 hours, and intracellular
staining for IFN-g and IL-10 was performed using anti-IFN-g PE
(XMG1.2; BD Biosciences) and anti-IL-10 antigen-presenting cell
(JES5-16E3; BD Bioscience) as described previously (Suto et al.,
2008).
Cell transfer experiments
CD4þ T cells and CD8þ T cells were isolated from the spleen of WT
mice or BTLA / mice by using PE-labeled anti-mouse CD4 anti-
body (eBioscience) and anti-mouse CD8 antibody (eBioscience),
respectively, and magnetic microbeads were coated with anti-PE
antibody (Miltenyi Biotec, Auburn, CA) according to the manufac-
turer’s instructions. Mixture of splenic CD4þ T cells (1 106 cells)
and CD8þ T cells (1 106 cells) from either WT mice or BTLA /
mice were transferred intravenously to SCID mice (7-weeks-old). The
recipient mice were sensitized and challenged with DNFB as
described above.
The effect of an agonistic anti-BTLA antibody on CHS
C57BL/6 mice were sensitized on the shaved abdomen with DNFB,
and 5 days later, mice were challenged with DNFB as described
above. Either just before or 24 hours after DNFB challenge, 200mg of
an agonistic anti-BTLA mAb (clone 6A6, hamster IgG) (Lepenies et al.,
2007) or control IgG was injected intraperitoneally to the mice. Ear
swelling and infiltrating leukocytes in the ear skin were evaluated as
described above.
Proliferation assay
WT mice and BTLA / mice were sensitized with 0.5% DNFB on
arms and legs (30ml each). Five days after the sensitization, single-cell
suspensions were prepared from inguinal and axillary LNs, and
CD4þ T cells and CD8þ T cells were isolated by magnetic cell
sorting as described above. CD62Llow CD4þ T cells and CD62Llow
CD8þ T cells were purified from isolated CD4þ T cells and CD8þ T
cells, respectively, by eliminating CD62Lhigh cells with anti-CD62L
antibody–conjugated microbeads (Miltenyi Biotec) according to the
manufacturer’s instructions. Purified CD62Llow CD4þ T cells or
CD62Llow CD8þ T cells (2 105 cells per well) were stimulated
with DNBS (100mg ml 1, Sigma-Aldrich) in the presence of
irradiated splenocytes (1 106 cells per well) as antigen-presenting
cells in a 96-well plate for 3 days. Cell proliferation was assessed
using Premix WST-1 Cell Proliferation Assay System (Takara Bio,
Shiga, Japan).
Measurement of cytokines
Isolated CD62Llow CD4þ T cells or CD62Llow CD8þ T cells were
stimulated with DNBS in the presence of irradiated splenocytes for 3
days as described above. The amounts of IFN-g and IL-4 in the culture
supernatants were measured by using murine ELISA kits for IFN-g and
IL-4, respectively (BD Biosciences). The assay was performed in
duplicate according to the manufacturer’s instructions. The detection
limits of these assays were 15 pg ml 1.
Data analysis
Data are summarized as mean±SD. The statistical analysis of the
results was performed by means of ANOVA or unpaired t-test as
appropriate. P-values o0.05 were considered significant.
CONFLICT OF INTEREST
The authors state no conflict of interest.
ACKNOWLEDGMENTS
We thank Ms A Ito for technical support and K Tokoyoda for valuable
discussion. This work was supported in part by Grants-in-Aid for Scientific
Research from the Ministry of Education, Culture, Sports, Science and
Technology, the Japanese government, and by Global COE Program (Global
Center for Education and Research in Immune System Regulation and
Treatment), MEXT, Japan.
SUPPLEMENTARY MATERIAL
Supplementary material is linked to the online version of the paper at http://
www.nature.com/jid
REFERENCES
Albring JC, Sandau MM, Rapaport AS et al. (2010) Targeting of B and T
lymphocyte associated (BTLA) prevents graft-versus-host disease without
global immunosuppression. J Exp Med 207:2551–9
Betts MR, Brenchley JM, Price DA et al. (2003) Sensitive and viable
identification of antigen-specific CD8þ T cells by a flow cytometric
assay for degranulation. J Immunol Methods 281:65–78
Cai G, Freeman GJ (2009) The CD160, LIGHT/HVEM pathway: a bidirectional
switch regulating T-cell activation. Immunol Rev 229:244–58
Cavani A (2008) T regulatory cells in contact hypersensitivity. Curr Opin
Allergy Clin Immunol 8:294–8
Chen L (2004) Co-inhibitory molecules of the B7-CD28 family in the control of
T-cell immunity. Nat Rev Immunol 4:336–47
Deppong C, Juehne TI, Hurchla M et al. (2006) B and T lymphocyte
attenuator and programmed death receptor-1 inhibitory receptors are
required for termination of acute allergic airway inflammation. J Immunol
176:3909–13
Derre´ L, Rivals J-P, Jandus C et al. (2010) BTLA mediates inhibition of human
tumor-specific CD8þ T cells that can be partially reversed by vaccination.
J Clin Invest 120:157–67
Dubois B, Chapat L, Goubier A et al. (2003) Innate CD4þ CD25þ regulatory T
cells are required for oral tolerance and inhibition of CD8þ T cells
mediating skin inflammation. Blood 102:3295–301
Gomez de Agu¨ero M, Vocanson M, Hacini-Rachinel F et al. (2012) Langerhans
cells protect from allergic contact dermatitis in mice by tolerizing
CD8(þ ) T cells and activating Foxp3(þ ) regulatory T cells. J Clin Invest
122:1700–11
D Nakagomi et al.
Inhibition of CHS by an Agonistic Anti-BTLA mAb
710 Journal of Investigative Dermatology (2013), Volume 133
Greenwald RJ, Freeman GJ, Sharpe AH (2005) The B7 family revisited. Annu
Rev Immunol 23:515–48
Groom JR, Luster AD (2011) CXCR3 in T cell function. Exp Cell Res 317:620–31
Kaplan DH, Igyarto BZ, Gaspari AA (2012) Early immune events in the
induction of allergic contact dermatitis. Nat Rev Immunol 12:114–24
Kaplan DH (2010) In vivo function of Langerhans cells and dermal dendritic
cells. Trends Immunol 31:446–51
Kehren J, Desvignes C, Krasteva M et al. (1999) Cytotoxicity is mandatory for
CD8þ T cell-mediated contact hypersensitivity. J Exp Med 189:779–86
Kish DD, Li X, Fairchild RL (2009) CD8 T cells producing IL-17 and IFN-g
initiate the innate immune response required for responses to antigen skin
challenge. J Immunol 182:5949–59
Krieg C, Boyman O, Fu YX et al. (2007) B and T lymphocyte attenuator
regulates CD8þ T cell-intrinsic homeostasis and memory cell generation.
Nat Immunol 8:162–71
Lepenies B, Pfeffer K, Hurchla MA et al. (2007) Ligation of B and T lymphocyte
attenuator prevents the genesis of experimental cerebral malaria.
J Immunol 179:4093–100
Liu X, Alexiou M, Martin-Orozco N et al. (2009) A critical role of B and T
lymphocyte attenuator in peripheral T cell tolerance induction. J Immunol
182:4516–20
Martin SF, Esser PR, Weber FC et al. (2011) Mechanisms of chemical-induced
innate immunity in allergic contact dermatitis. Allergy 66:1152–63
Martin SF (2004) T lymphocyte-mediated immune responses to chemical
haptens and metal ions: implications for allergic and autoimmune disease.
Int Arch Allergy Immunol 134:186–98
Murphy KM, Nelson CA, Sedy JR (2006) Balancing co-stimulation and
inhibition with BTLA and HVEM. Nat Rev Immunol 6:671–81
Murphy TL, Murphy KM (2010) Slow down and survive: enigmatic immuno-
regulation by BTLA and HVEM. Annu Rev Immunol 28:389–411
Nuriya S, Enomoto S, Azuma M (2001) The role of CTLA-4 in murine contact
hypersensitivity. J Invest Dermatol 116:764–8
Ring S, Schafer SC, Mahnke K et al. (2006) CD4þ CD25þ regulatory T cells
suppress contact hypersensitivity reactions by blocking influx of effector T
cells into inflamed tissue. Eur J Immunol 36:2981–92
Serriari N-E, Gondois-Rey F, Guillaume Y et al. (2010) B and T lymphocyte
attenuator is highly expressed on CMV-specific T cells during infection
and regulates their function. J Immunol 185:3140–8
Suto A, Kashiwakuma D, Kagami S et al. (2008) Development and character-
ization of IL-21-producing CD4þ T cells. J Exp Med 205:1369–79
Tamachi T, Watanabe N, Oya Y et al. (2007) B and T lymphocyte attenuator
inhibits antigen-induced eosinophil recruitment into the airways. Int Arch
Allergy Immunol 143:s50–5
Tao R, Wang L, Han R et al. (2005) Differential effects of B and T lymphocyte
attenuator and programmed death-1 on acceptance of partially versus
fully MHC-mismatched cardiac allografts. J Immunol 175:5774–82
Tao R, Wang L, Murphy KM et al. (2008) Regulatory T cell expression of
herpesvirus entry mediator suppresses the function of B and T lymphocyte
attenuator-positive effector T cells. J Immunol 180:6649–55
Tsushima F, Iwai H, Otsuki N et al. (2003) Preferential contribution of B7-H1
to programmed death-1-mediated regulation of hapten-specific allergic
inflammatory responses. Eur J Immunol 33:2773–82
Usatine RP, Riojas M (2010) Diagnosis and management of contact dermatitis.
Am Fam Physician 82:249–55
Vocanson M, Rozieres A, Hennino A et al. (2010) Inducible costimulator
(ICOS) is a marker for highly suppressive antigen-specific T cells sharing
features of TH17/TH1 and regulatory T cells. J Allergy Clin Immunol
126:280–9
Vocanson M, Hennino A, Rozieres A et al. (2009) Effector and regulatory
mechanisms in allergic contact dermatitis. Allergy 64:1699–714
Watanabe N, Gavrieli M, Sedy JR et al. (2003) BTLA is a lymphocyte inhibitory
receptor with similarities to CTLA-4 and PD-1. Nat Immunol 4:670–9
Zhang N, Bevan MJ (2011) CD8þ T cells: foot soldiers of immune system.
Immunity 35:161–8
D Nakagomi et al.
Inhibition of CHS by an Agonistic Anti-BTLA mAb
www.jidonline.org 711
